Oncopeptides AB (publ)
ONPPF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.00 | 0.09 | 0.15 |
| FCF Yield | 0.00% | -11.40% | -31.77% | 2.05% |
| EV / EBITDA | -9.69 | -6.85 | -4.54 | -2.17 |
| Quality | ||||
| ROIC | -47.07% | -43.63% | -22.31% | -21.77% |
| Gross Margin | 100.63% | 92.67% | 91.76% | 88.39% |
| Cash Conversion Ratio | 0.86 | 2.13 | -0.12 | 0.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 61.39% | 55.88% | – | -19.73% |
| Free Cash Flow Growth | 0.00% | 45.21% | -1,587.00% | 113.03% |
| Safety | ||||
| Net Debt / EBITDA | -0.19 | 0.68 | 2.17 | 3.66 |
| Interest Coverage | -75.93 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | -0.01 | 0.17 | 0.16 | 0.20 |
| Cash Conversion Cycle | 5,185.67 | -1,708.39 | -606.46 | -381.29 |